Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT3 | Q9Y243 | 13/20 | 0.71 |
| ▸ | CLK1 | P49759 | 1/20 | 0.51 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.49 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.48 |
| ▸ | IKBKB | O14920 | 2/20 | 0.47 |
| ▸ | CHUK | O15111 | 2/20 | 0.47 |
| ▸ | IKBKG | Q9Y6K9 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3972858 | 0.91 | AKT3 (0.57) | AKT3CLK1IKBKBHDAC1 | |
| SCHEMBL3972321 | 0.89 | AKT3 (0.73) | AKT3IKBKBCHUKIKBKGHDAC1 | |
| SCHEMBL5000573 | 0.86 | AKT3 (0.78) | AKT3 | |
| SCHEMBL4925751 | 0.86 | AKT3 (0.63) | AKT3RAB9AHDAC1 | |
| SCHEMBL3972126 | 0.85 | AKT3 (0.70) | AKT3IKBKBCHUKIKBKG | |
| SCHEMBL4919836 | 0.85 | AKT3 (0.52) | AKT3NPC1RAB9A | |
| SCHEMBL12423295 | 0.84 | AKT3 (0.55) | AKT3CLK1ACKR3 | |
| SCHEMBL5000430 | 0.84 | AKT3 (0.75) | AKT3IKBKBCHUKIKBKGNPC1 | |
| SCHEMBL12423373 | 0.84 | AKT3 (0.71) | AKT3IKBKBNPC1RAB9AHDAC1 | |
| SCHEMBL5003717 | 0.83 | AKT3 (1.00) | AKT3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1907385-A4 | COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2009-05-06 | — | — | EP | disclosed |
| US-20080293716-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2008-11-27 | — | — | US | disclosed |
| US-20080293716-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2008-11-27 | — | — | US | disclosed |
| US-20080293716-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2008-11-27 | — | — | US | disclosed |
| US-20080194561-A1 | carboxyamide thiophenes and medicaments containing the same as well as processes for the preparation and use of such compounds, compositions and medicaments, particularly in diseases associated with inappropriate Aurora activity. | SMITHKLINE BEECHAM CORPORATION | 2008-08-14 | — | — | US | disclosed |
| US-20080194561-A1 | carboxyamide thiophenes and medicaments containing the same as well as processes for the preparation and use of such compounds, compositions and medicaments, particularly in diseases associated with inappropriate Aurora activity. | SMITHKLINE BEECHAM CORPORATION | 2008-08-14 | — | — | US | disclosed |
| US-20080194561-A1 | carboxyamide thiophenes and medicaments containing the same as well as processes for the preparation and use of such compounds, compositions and medicaments, particularly in diseases associated with inappropriate Aurora activity. | SMITHKLINE BEECHAM CORPORATION | 2008-08-14 | — | — | US | disclosed |
| EP-1907385-A2 | COMPOUNDS | SmithKline Beecham Corporation (US) | 2008-04-09 | — | — | EP | disclosed |
| EP-1708697-A4 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2007-11-28 | — | — | EP | disclosed |
| WO-2007018941-A2 | PYRIMIDYL-THIOPHENE DERIVATIVES | SMITHKLINE BEECHAM CORPORATION (US) | 2007-02-15 | — | — | WO | disclosed |
| WO-2007018941-A2 | PYRIMIDYL-THIOPHENE DERIVATIVES | SMITHKLINE BEECHAM CORPORATION (US) | 2007-02-15 | — | — | WO | disclosed |
| EP-1708697-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-11 | — | — | EP | disclosed |
| WO-2005074642-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293716-A1 | Chemical Compounds | CYP11B2, CYP11B1, REN | AKT3 1872/4885CLK1 3529/4885PDE10A 316/4885 |
| US-20080194561-A1 | carboxyamide thiophenes and medicaments containing the same as well as processes for the preparation and use of such compounds, compositions and medicaments, particularly in diseases associated with inappropriate Aurora activity. | AURKA, AURKC, AURKB | AKT3 3904/4885CLK1 1237/4885PDE10A 4010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.